沉淀疏水性可注射液体(PHIL®)栓塞外周动静脉畸形和动静脉瘘
单次栓塞技术成功率50%,全部患者临床改善且无技术失败,2例少量反流至非靶血管无临床影响。作者认为PHIL®似乎安全有效,但未与Onyx直接比较。
要点
- 单次PHIL®栓塞后技术成功率为50%,但全部患者获得临床改善且无需额外治疗。
- 2例出现少量PHIL®近端反流至非靶血管,均无临床影响。
- 浅表病变未见染色效应,CT及锥形束CT控制扫描未见伪影。
核心结论
- PHIL®似乎是治疗外周动静脉畸形和动静脉瘘的安全有效的液体栓塞剂。
研究设计与样本
- 单中心初步经验,纳入7例男性和5例女性,平均年龄42.16岁,其中10例为首次栓塞治疗、2例曾接受Onyx®栓塞。
关键影像表现/征象
- 病变位于小肠(1例)、结肠(1例)、头面部(5例)、前足(1例)、子宫(1例)和胸部(3例),均有症状;栓塞后30天临床随访,术后3个月行增强CT或MR检测病变残留。
临床应用与阅片要点
- PHIL®经动脉途径注射,同一操作中不使用其他栓塞剂;术后3个月增强CT或MR用于检测病变残留。
局限性
- 原文为初步经验,未与Onyx进行直接比较。
- PHIL®因每包装产品体积较低而更昂贵,且在透视下 radiopacity 稍低(原文表述)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This paper reports on the preliminary experience of a single center in the embolization of peripheral AVMs and fistulas with precipitating hydrophobic injectable liquid (PHIL®), focusing on technical aspects and short-term clinical outcomes.
MATERIALS AND METHODS: Seven males and five females were included in this study, mean age 42.16 years. For ten of them, it was the first embolization treatment; two had been previously treated with Onyx® embolization. PHIL® was injected with a transarterial approach without other embolics during the same procedure. Lesions were localized in small bowel (1), colon (1), head face (5), forefoot (1), uterus (1) and thorax (3); all were symptomatic. After 30-day clinical follow-up, a contrast-enhanced CT or MR was acquired at 3 months from intervention to detect eventual lesion residual.
RESULTS: After a single embolization procedure, complete technical success was obtained in 50%, while clinical improvement without additional therapies was appreciable in all patients. No technical failure occurred; in two cases, a small amount of PHIL® proximally refluxed in nontarget vessels without clinical effects. No tattooing effects of superficial lesions neither artifacts at CT and cone-beam CT controls were evident.
CONCLUSIONS: PHIL® seems to be a safe and effective liquid embolic agent for the treatment of peripheral AVMs and fistulas; although a direct comparison between PHIL and Onyx was not performed, PHIL might present the advantages of reduced artifacts at postprocedural CT scan and no need for shaking time preparation, but it is more expensive due to lower volume of product for each package and slightly less radiopaque at fluoroscopy.
引用
- Giurazza F, Corvino F, Silvestre M, et al. Embolization of peripheral arteriovenous malformations and fistulas with precipitating hydrophobic injectable liquid (PHIL®). Radiol Med. 2020. PMID: 32889705. doi:10.1007/s11547-020-01274-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。